PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
October 10, 2025Blood Advances5 citationsOpen Access

Myeloid landscape profiling identifies DLBCL-specific suppressive macrophages colocalized with blood endothelial cells

View Full Paper
JFJuliette FerrantSGSimon Le GallouFPFrancine Padonou

Key Points

  • A unique pattern of tumor-associated macrophages was found in DLBCL, emphasizing their role in the tumor microenvironment.
  • Mass cytometry and single-cell RNA sequencing revealed important interactions between macrophages and blood endothelial cells in DLBCL.
  • The study uncovered a spatial connection between specific macrophages and endothelial cells, linked to immune suppression.
  • Findings suggest that the macrophage-endothelial interaction could contribute to poor prognosis in DLBCL patients.

Abstract

Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are the two most common B-cell lymphomas and are characterized by a dynamic crosstalk between tumor B cells and a heterogeneous tumor-supportive microenvironment, including immune, endothelial, and stromal components. Despite their recognized impact on the pathogenesis and prognosis of B-cell lymphoma, tumor-associated macrophages (TAM) have not been extensively explored in these diseases. Herein, we investigated mononuclear phagocyte (MNP) heterogeneity at the single-cell level and the activation profile of MNP, stromal, and endothelial compartments in B-cell lymphoma lymph nodes compared to reactive secondary lymphoid organs. This was achieved using a combination of mass cytometry, single-cell RNA sequencing, in silico and spatial imaging approaches. Our findings revealed a lymphoma-specific pattern of TAM and blood endothelial cell (BEC) co-activation. Furthermore, we identified in DLBCL a spatial interaction between Annexin A1 (ANXA1)-expressing BEC and formyl-peptide receptor (FPR1/2) and S100A9-expressing monocytes/macrophages. This crosstalk is associated with an immunosuppressive tumor microenvironment and an adverse prognosis in two cohorts of DLBCL patients.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ferrant et al. (2025) studied this question.

synapsesocial.com/papers/68e8619c7ef2f04ca37e43e0https://doi.org/10.1182/bloodadvances.2024015689
Ask AI
Helpful
Bookmark
Share
View Full Paper